CA3058503A1 - Isoflavonoid composition with improved pharmacokinetics - Google Patents

Isoflavonoid composition with improved pharmacokinetics Download PDF

Info

Publication number
CA3058503A1
CA3058503A1 CA3058503A CA3058503A CA3058503A1 CA 3058503 A1 CA3058503 A1 CA 3058503A1 CA 3058503 A CA3058503 A CA 3058503A CA 3058503 A CA3058503 A CA 3058503A CA 3058503 A1 CA3058503 A1 CA 3058503A1
Authority
CA
Canada
Prior art keywords
formula
compound
formulation
suppository
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3058503A
Other languages
English (en)
French (fr)
Inventor
Graham Kelly
Kate PORTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noxopharm Ltd
Original Assignee
Noxopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU2016/050674 external-priority patent/WO2017173474A1/en
Application filed by Noxopharm Ltd filed Critical Noxopharm Ltd
Publication of CA3058503A1 publication Critical patent/CA3058503A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3058503A 2016-04-06 2017-04-06 Isoflavonoid composition with improved pharmacokinetics Abandoned CA3058503A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662318946P 2016-04-06 2016-04-06
US62/318,946 2016-04-06
AUPCT/AU2016/050674 2016-07-28
PCT/AU2016/050674 WO2017173474A1 (en) 2016-04-06 2016-07-28 Improvements in cancer treatment
US201762480692P 2017-04-03 2017-04-03
US62/480,692 2017-04-03
PCT/AU2017/050301 WO2017173498A1 (en) 2016-04-06 2017-04-06 Isoflavonoid composition with improved pharmacokinetics

Publications (1)

Publication Number Publication Date
CA3058503A1 true CA3058503A1 (en) 2017-10-12

Family

ID=60000544

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3058503A Abandoned CA3058503A1 (en) 2016-04-06 2017-04-06 Isoflavonoid composition with improved pharmacokinetics

Country Status (6)

Country Link
US (1) US11559510B2 (enExample)
EP (2) EP3439644B1 (enExample)
JP (1) JP2019513828A (enExample)
AU (1) AU2017247008B2 (enExample)
CA (1) CA3058503A1 (enExample)
WO (1) WO2017173498A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3439642A4 (en) * 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIOTHERAPY
CA3058500A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Targeted drug delivery
AU2017247008B2 (en) 2016-04-06 2022-04-07 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
WO2021007618A1 (en) * 2019-07-17 2021-01-21 Noxopharm Limited Immuno-oncology therapy using isoflavone compounds
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0676314B2 (ja) * 1985-09-30 1994-09-28 花王株式会社 坐剤基剤及び坐剤
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AUPQ008299A0 (en) 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
US20090233999A1 (en) 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
EP1503751A4 (en) 2002-04-09 2007-08-01 Novogen Res Pty Ltd THERAPEUTIC PROCESSES AND COMPOSITIONS WITH ISOFLAV-3-EN AND ISOFLAVAN STRUCTURES
CA2492754C (en) 2002-07-24 2018-05-22 Children's Hospital Medical Center Compositions and products containing enantiomeric equol, and methods for their making
AU2002951833A0 (en) 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
AU2002952453A0 (en) 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
AU2004273910A1 (en) 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
JP2007525485A (ja) * 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
US20050154452A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US7434690B2 (en) 2004-04-30 2008-10-14 Cutispharma, Inc. Container and method for the preparation, storage and dispensing of compounded suppositories
ATE532777T1 (de) 2004-09-21 2011-11-15 Marshall Edwards Inc Substituierte chromanderivate, medikamente und anwendungen in der therapie
WO2006032086A1 (en) 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy
DE102005009515A1 (de) 2005-02-25 2006-09-07 Exner, Heinrich, Dr. Verfahren zur Herstellung einer Zubereitung einer DMSO-haltigen festen Silikonölemulsion zur Bindung von reaktiven Sauerstoffverbindungen im Körper von Menschen und Tieren
CN101203219B (zh) 2005-03-24 2011-06-15 诺沃根研究控股有限公司 消炎用药程式
EP1948103A2 (en) 2005-09-15 2008-07-30 UMD, Inc. A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration
US20070196381A1 (en) 2006-02-17 2007-08-23 Natures Benefit, Inc. Herbal compositions, methods of stimulating immunomodulation and enhancement of immunomodulating agents using the herbal compositions
WO2008052256A1 (en) * 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
EP2160385A4 (en) * 2007-06-29 2010-10-27 Novogen Res Pty Ltd 2-SUBSTITUTED ISOFLAVONOID COMPOUNDS AND MEDICAMENTS THEREOF AND APPLICATIONS THEREOF
EP2334296A4 (en) 2008-08-29 2012-04-25 Novogen Res Pty Ltd IMMUNOMODULATING ACTIVITIES
EP2365955B1 (en) 2008-11-14 2014-12-31 Heartlink Limited Aryl di-substituted propenone compounds
KR20110004525A (ko) * 2009-07-08 2011-01-14 동의대학교 산학협력단 제니스테인과 ｔｒａｉｌ을 포함하는 간암 치료용 조성물
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
KR20220123335A (ko) 2013-03-13 2022-09-06 온코슈틱스 인코포레이티드 7-벤질-10-(2-메틸벤질)-2,6,7,8,9,10-헥사하이드로이미다조[1,2-a]피리도[4,3-d]피리미딘-5(3h)-온과의 조합 치료요법
US20150126597A1 (en) 2013-11-07 2015-05-07 Humanetics Corporation Genistein cancer treatment regimen maximizing cancer radiation therapy benefits
PL2953938T3 (pl) 2014-02-07 2017-12-29 Novogen Ltd. Funkcjonalizowane związki benzopiranowe i ich zastosowanie
HRP20220738T1 (hr) 2014-08-11 2022-08-19 Acerta Pharma B.V. Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP4512394A3 (en) * 2015-06-03 2025-10-22 Triastek, Inc. Dosage forms and use thereof
US10561653B2 (en) 2015-08-11 2020-02-18 Novartis Ag 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
KR20190016017A (ko) 2016-04-06 2019-02-15 녹소팜 리미티드 암 치료제의 개선
AU2017247008B2 (en) 2016-04-06 2022-04-07 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
EP4035667A1 (en) * 2016-04-22 2022-08-03 Noxopharm Limited Chemotherapy improvements with idronoxil
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
AU2019285641A1 (en) 2018-06-15 2021-04-08 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
AU2019285640A1 (en) 2018-06-15 2021-01-21 Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
WO2020051644A1 (en) 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation

Also Published As

Publication number Publication date
US11559510B2 (en) 2023-01-24
EP3439644A1 (en) 2019-02-13
US20190117618A1 (en) 2019-04-25
AU2017247008B2 (en) 2022-04-07
EP4005567A1 (en) 2022-06-01
AU2017247008A1 (en) 2018-11-01
EP3439644A4 (en) 2019-10-30
EP3439644B1 (en) 2022-01-12
JP2019513828A (ja) 2019-05-30
WO2017173498A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
AU2017247008B2 (en) Isoflavonoid composition with improved pharmacokinetics
US20260027079A1 (en) Cannabinoid acid ester compositions and uses thereof
AU2012330885B2 (en) Oral immediate release formulations for substituted quinazolinones
JP7193591B2 (ja) 化学療法の改善
RU2508116C2 (ru) Способ и композиции для лечения рака
CN107405347B (zh) 用于治疗处理或美容处理过量体脂肪的nk-3受体拮抗剂
AU2005253720A1 (en) Pharmaceutical compositions containing polyunsaturated fatty acid and at least one of an immunosuppressive agent or an antineoplastic agent
CN112654626A (zh) 化合物及其用途
AU2016401508B2 (en) Improvements in cancer treatment
CN110402142A (zh) 含局麻药的酸性乳液组合物
KR20070059154A (ko) 비수계의 액상 비경구 아세클로페낙 제제
JP7105465B2 (ja) キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物及び懸濁液注射剤の製造方法
WO2025093572A1 (en) Solid dispersion compositions and uses thereof
HK40006250A (en) Improvements in cancer treatment
JP6105977B2 (ja) がん化学療法剤に起因する末梢神経障害予防剤及び／又は治療剤
HK40111798A (zh) 大麻素酸酯组合物及其用途
CN102258466A (zh) 含笑内酯脂质微球注射液及其制备方法
EP2699236A1 (en) Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga)

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230704